BIOMAT Database Logo BIOMAT Database Logo

Efficacy of triple combination therapy with zidovudine (ZDV) plus zalcitabine (ddC) plus lamivudine (3TC) versus double (ZDV+3TC) combination therapy in patients previously treated with ZDV+ddC. 1996

L Ruiz, and J Romeu, and J Martínez-Picado, and J C Schmit, and A M Vandamme, and M Balagué, and C Cabrera, and T Puig, and C Tural, and A Segura, and G Sirera, and E De Clercq, and B Clotet
Retrovirology Laboratory Institut de Recerca de la SIDA-Caixa, Spain.

OBJECTIVE To evaluate the immunological and virological efficacy of triple combination therapy with zidovudine (ZDV) plus zalcitabine (ddC) plus lamivudine (3TC) and a double (ZDV+3TC) combination therapy in patients previously treated with ZDV plus ddC. METHODS A 6-month follow-up open-label randomized study was undertaken in 46 HIV-1-infected patients previously treated for at least 6 months with ZDV plus ddC, who were allocated to receive either ZDV/ddC/3TC (n = 15) or ZDV/3TC (n = 15) or to continue with the ZDV/ddC regimen (control group; n = 16). METHODS Changes in CD4+ cell counts and plasma viral load (VL) were analysed with analysis of variance. Sequencing of the reverse transcriptase gene was performed in a subset of 3TC-treated patients. RESULTS Mean CD4+ cell counts increased significantly above baseline in both 3TC regimens whereas counts decreased in the control group. Significant plasma VL reduction was achieved in both 3TC combination therapy groups at weeks 4 and 24 compared with the control group. Coexistence of mutations conferring resistance to ZDV and 3TC were found in patients from both 3TC treatment groups. CONCLUSIONS Both therapy strategies, switching ddC to 3TC or adding 3TC, significantly improved the virological and immunological efficacy compared with continuing ZDV/ddC. Our results support the use of 3TC in patients previously treated with the ZDV/ddC combination.

UI MeSH Term Description Entries
D008297 Male Males
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D015215 Zidovudine A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia. AZT (Antiviral),Azidothymidine,3'-Azido-2',3'-Dideoxythymidine,3'-Azido-3'-deoxythymidine,AZT Antiviral,AZT, Antiviral,BW A509U,BWA-509U,Retrovir,3' Azido 2',3' Dideoxythymidine,3' Azido 3' deoxythymidine,Antiviral AZT,BWA 509U,BWA509U
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human
D016047 Zalcitabine A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication at low concentrations, acting as a chain-terminator of viral DNA by binding to reverse transcriptase. Its principal toxic side effect is axonal degeneration resulting in peripheral neuropathy. 2',3'-Dideoxycytidine,Dideoxycytidine,ddC (Antiviral),HIVID Roche,Hivid,NSC-606170,2',3' Dideoxycytidine,NSC 606170,NSC606170
D019259 Lamivudine A reverse transcriptase inhibitor and ZALCITABINE analog in which a sulfur atom replaces the 3' carbon of the pentose ring. It is used to treat HIV disease. 2',3'-Dideoxy-3'-thiacytidine,2(1H)-Pyrimidinone, 4-amino-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-, (2R-cis)-,3TC Lamivudine,Lamivudine, (+)-cis-,Lamivudine, (+-)-trans-,BCH-189,Epivir,GR-109714X,GR109714X,Lamivudine, (2S-cis)-Isomer,2',3' Dideoxy 3' thiacytidine,BCH 189,BCH189,GR 109714X,Lamivudine, 3TC

Related Publications

L Ruiz, and J Romeu, and J Martínez-Picado, and J C Schmit, and A M Vandamme, and M Balagué, and C Cabrera, and T Puig, and C Tural, and A Segura, and G Sirera, and E De Clercq, and B Clotet
Drug resistance and virologic response in NUCA 3001, a randomized trial of lamivudine (3TC) versus zidovudine (ZDV) versus ZDV plus 3TC in previously untreated patients.
August 1996, AIDS (London, England),
L Ruiz, and J Romeu, and J Martínez-Picado, and J C Schmit, and A M Vandamme, and M Balagué, and C Cabrera, and T Puig, and C Tural, and A Segura, and G Sirera, and E De Clercq, and B Clotet
Zidovudine (ZDV) and Lamivudine (3TC) Combination Therapy for HIV Infection - A Review.
February 1998, The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases,
L Ruiz, and J Romeu, and J Martínez-Picado, and J C Schmit, and A M Vandamme, and M Balagué, and C Cabrera, and T Puig, and C Tural, and A Segura, and G Sirera, and E De Clercq, and B Clotet
Combination therapy with ZDV + DDI versus ZDV + DDC in patients with progression of HIV-infection under treatment with ZDV.
April 1996, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association,
L Ruiz, and J Romeu, and J Martínez-Picado, and J C Schmit, and A M Vandamme, and M Balagué, and C Cabrera, and T Puig, and C Tural, and A Segura, and G Sirera, and E De Clercq, and B Clotet
Zidovudine (AZT) versus AZT plus didanosine (ddI) versus AZT plus zalcitabine (ddC) in HIV infected adults.
January 2000, The Cochrane database of systematic reviews,
L Ruiz, and J Romeu, and J Martínez-Picado, and J C Schmit, and A M Vandamme, and M Balagué, and C Cabrera, and T Puig, and C Tural, and A Segura, and G Sirera, and E De Clercq, and B Clotet
Zidovudine (AZT) versus AZT plus didanosine (ddI) versus AZT plus zalcitabine (ddC) in HIV infected adults.
January 2000, The Cochrane database of systematic reviews,
L Ruiz, and J Romeu, and J Martínez-Picado, and J C Schmit, and A M Vandamme, and M Balagué, and C Cabrera, and T Puig, and C Tural, and A Segura, and G Sirera, and E De Clercq, and B Clotet
Dual resistance to zidovudine and lamivudine in patients treated with zidovudine-lamivudine combination therapy: association with therapy failure.
June 1998, The Journal of infectious diseases,
L Ruiz, and J Romeu, and J Martínez-Picado, and J C Schmit, and A M Vandamme, and M Balagué, and C Cabrera, and T Puig, and C Tural, and A Segura, and G Sirera, and E De Clercq, and B Clotet
Combined effect of zidovudine (ZDV), lamivudine (3TC) and abacavir (ABC) antiretroviral therapy in suppressing in vitro FIV replication.
January 2002, Antiviral research,
L Ruiz, and J Romeu, and J Martínez-Picado, and J C Schmit, and A M Vandamme, and M Balagué, and C Cabrera, and T Puig, and C Tural, and A Segura, and G Sirera, and E De Clercq, and B Clotet
Lamivudine plus zidovudine compared with zalcitabine plus zidovudine in patients with HIV infection. A randomized, double-blind, placebo-controlled trial. North American HIV Working Party.
August 1996, Annals of internal medicine,
L Ruiz, and J Romeu, and J Martínez-Picado, and J C Schmit, and A M Vandamme, and M Balagué, and C Cabrera, and T Puig, and C Tural, and A Segura, and G Sirera, and E De Clercq, and B Clotet
AVANTI 2. Randomized, double-blind trial to evaluate the efficacy and safety of zidovudine plus lamivudine versus zidovudine plus lamivudine plus indinavir in HIV-infected antiretroviral-naive patients.
March 2000, AIDS (London, England),
L Ruiz, and J Romeu, and J Martínez-Picado, and J C Schmit, and A M Vandamme, and M Balagué, and C Cabrera, and T Puig, and C Tural, and A Segura, and G Sirera, and E De Clercq, and B Clotet
A randomized, double-blind study of triple nucleoside therapy of abacavir, lamivudine, and zidovudine versus lamivudine and zidovudine in previously treated human immunodeficiency virus type 1-infected children. The CNAA3006 Study Team.
January 2001, Pediatrics,
Copied contents to your clipboard!